We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
One Step Closer to a Diagnostic Test for Schizophrenia
News

One Step Closer to a Diagnostic Test for Schizophrenia

One Step Closer to a Diagnostic Test for Schizophrenia
News

One Step Closer to a Diagnostic Test for Schizophrenia

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "One Step Closer to a Diagnostic Test for Schizophrenia"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Schizophrenia is a chronic and severe psychotic disorder that affects around 1% of the population. Currently, there is no clinical test for diagnosing schizophrenia, and therefore the condition is usually recognized and treated on the basis of patient symptoms.

A new study performed by Matej Orešič and colleagues from VTT Technical Research Centre of Finland in collaboration with Jaana Suvisaari from the Finnish National Institute for Health and Welfare reveals metabolic abnormalities that are associated specifically with schizophrenia, as opposed to other psychotic disorders.

These findings, which were published in Genome Medicine in March 2011, might be an important step towards the development of a clinical diagnostic test for schizophrenia.

The team used metabolomics, a high-throughput method for detecting small metabolites, to produce profiles of the serum metabolites associated with schizophrenia, other nonaffective psychosis (ONAP) or affective psychosis.

Their analysis indicates that schizophrenia is associated with elevated serum levels of specific triglycerides, indicative of hyperinsulinemia, and also upregulation of the serum amino acid proline. Orešič et al. then combined these metabolic profiles to create a diagnostic model with the potential to discriminate schizophrenia from other psychoses.

This exciting study demonstrates how metabolomics can be a powerful tool for dissecting disease-related metabolic pathways and for identifying candidate diagnostic and prognostic markers in psychiatric research.

Advertisement